GR3007663T3 - - Google Patents

Info

Publication number
GR3007663T3
GR3007663T3 GR930400343T GR930400343T GR3007663T3 GR 3007663 T3 GR3007663 T3 GR 3007663T3 GR 930400343 T GR930400343 T GR 930400343T GR 930400343 T GR930400343 T GR 930400343T GR 3007663 T3 GR3007663 T3 GR 3007663T3
Authority
GR
Greece
Prior art keywords
salt
acid
formulation
salts
intravenous
Prior art date
Application number
GR930400343T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3007663T3 publication Critical patent/GR3007663T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
GR930400343T 1988-10-21 1993-04-15 GR3007663T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/260,628 US4973591A (en) 1988-10-21 1988-10-21 Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine

Publications (1)

Publication Number Publication Date
GR3007663T3 true GR3007663T3 (el) 1993-08-31

Family

ID=22989940

Family Applications (1)

Application Number Title Priority Date Filing Date
GR930400343T GR3007663T3 (el) 1988-10-21 1993-04-15

Country Status (14)

Country Link
US (1) US4973591A (el)
EP (1) EP0365363B1 (el)
JP (1) JPH02157224A (el)
KR (1) KR900005962A (el)
AT (1) ATE88094T1 (el)
AU (1) AU636581B2 (el)
CA (1) CA2001170A1 (el)
DE (1) DE68905995T2 (el)
DK (1) DK523389A (el)
ES (1) ES2057145T3 (el)
GR (1) GR3007663T3 (el)
IE (1) IE63292B1 (el)
NZ (1) NZ231094A (el)
ZA (1) ZA897975B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276035A (en) * 1990-07-26 1994-01-04 Novo Nordisk A/S 1,4-disubstituted piperazines
DK178590D0 (da) * 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
SE469717B (sv) * 1992-02-20 1993-08-30 Ingemar Naeslund Klaemma, speciellt foer tillslutning av paasar
JPH08511005A (ja) * 1993-06-01 1996-11-19 コーテックス ファーマシューティカルズ インコーポレイテッド 神経疾患の治療におけるアルカリ性または酸性ホスファターゼインヒビター
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
GB1184714A (en) * 1965-12-16 1970-03-18 Science Union & Cie Di- and Tri-Phenylpropyl Piperazine Derivatives
US3491098A (en) * 1967-05-29 1970-01-20 Sterling Drug Inc 1-((imidazolyl)-lower-alkyl)-4-substituted-piperazines
DE1795314A1 (de) * 1968-09-11 1972-01-05 Merck Patent Gmbh N-(Thiazolyl-2)-piperazine
US3927011A (en) * 1973-05-10 1975-12-16 Yoshitomi Pharmaceutical 2-Aminoalkyl-1-(pyridylcarbonylphenyl)imidazole compounds
US4022783A (en) * 1975-10-29 1977-05-10 Usv Pharmaceutical Corporation Piperazinyl-imidazolines
GB1551993A (en) * 1976-09-21 1979-09-05 Malesci Sas Pharmacologiclly active derivatives of 1 alkyl 4-phenylpiperazines and the preparation thereof
IT1159698B (it) * 1978-05-29 1987-03-04 Rotta Research Lab Derivati 5-nitro-imidazolici della piperazina ad attivita' antiprotozoica
US4243806A (en) * 1979-06-13 1981-01-06 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
US4404382A (en) * 1980-09-17 1983-09-13 The Upjohn Company Piperazinyl-substituted imidazoles
CA1162540A (en) * 1980-12-24 1984-02-21 Ikutaro Saji Imidazolylpropanol compounds and their acid addition salts, and production and use thereof
US4435399A (en) * 1981-07-18 1984-03-06 Pfizer Inc. 2-Aryl-1-(imidazol-1-yl)-8-(4-piperazin-1-ylphenoxy) octan-2-ol antifungal agents
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

Also Published As

Publication number Publication date
ES2057145T3 (es) 1994-10-16
EP0365363B1 (en) 1993-04-14
NZ231094A (en) 1991-12-23
IE63292B1 (en) 1995-04-05
EP0365363A1 (en) 1990-04-25
ATE88094T1 (de) 1993-04-15
DE68905995D1 (de) 1993-05-19
CA2001170A1 (en) 1990-04-21
JPH02157224A (ja) 1990-06-18
AU636581B2 (en) 1993-05-06
US4973591A (en) 1990-11-27
KR900005962A (ko) 1990-05-07
DK523389D0 (da) 1989-10-20
IE893382L (en) 1990-04-21
ZA897975B (en) 1991-06-26
DK523389A (da) 1990-04-22
AU4356989A (en) 1990-04-26
DE68905995T2 (de) 1993-09-16

Similar Documents

Publication Publication Date Title
Wang et al. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys
Greenstein Naltrexone: a clinical perspective.
KR910019630A (ko) 프라바스타틴 및 제약상 허용되는 담체로 이루어진 혈관형성수술후의 재협착 발생 방지용 제약 조성물
US4619939A (en) Process for reducing intraocular pressure
GB2108388A (en) Composition and method for treating alcohol and drug addicts
SE9002500D0 (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
GR3007663T3 (el)
EP0634932A1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
GR3005834T3 (el)
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
WO1993012796A1 (en) Use of renin inhibitors for the treatment of glaucoma
US4746745A (en) 1,3,4-thiadiazoline-5-sulfonamides
FI95777C (fi) Menetelmä 8-N-(dietyyliaminoetyyli)rebekkamysiinin stabiilin vesiliuoksen valmistamiseksi
SASSOLAS et al. Effects on growth hormone secretion following intravenous and subcutaneous injections of growth hormone‐releasing factor (hGRF‐44 NH2): comparison of immunoreactive plasma GRF levels
KR890012961A (ko) N-(저급알킬)-2-(3'-우레이도벤질)피롤리딘
DE3380294D1 (en) Pharmaceutical compositions in oral dosage form
Fedorak et al. Inhibition of cholera-toxin-stimulated intestinal secretion by CGS 9343B in rats: a specific calmodulin inhibitor
MX9603766A (es) Metodos de administracion de benzamidas n-substituidas o fenotiazinas.
Gordon et al. Preclinical ocular irritation findings with dorzolamide hydrochloride
GB2155331A (en) Composition for reducing intraocular pressure
JPS5533446A (en) Amino acid transfusion for postoperative patient
EP0229963A3 (en) 4-thienyl-dihydropyridines, process for their preparation and their use as pharmaceutical preparations
DK0421707T3 (da) Forbedringer i behandlingen af ufrugtbarhed
Daniels et al. 4 2. PHYSICOCHEMICAL PROPERTIES IN RELATION TO BIOLOGiC ACTION
JPS56115722A (en) Analgesic